## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($88.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. First Trust Advisors LP Acquires 217,595 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251207T113206 | Somewhat-Bullish | Relevance: 99%
-  First Trust Advisors LP increased its stake in AstraZeneca PLC by 24.4% in the second quarter, purchasing an additional 217,595 shares to bring its total holdings to 1,109,464 shares valued at approximately $77.53 million. The pharmaceutical company has a "Moderate Buy" consensus rating from analysts with a target price of $91.67, and recently reported strong quarterly results with EPS of $1.19 and revenue of $15.19 billion, exceeding expectations. AstraZeneca's stock is currently trading near $90, with a market capitalization of around $280 billion.

**2. AstraZeneca is top pharma tip for 2026, with GSK left trailing**
- Source: Proactive financial news | 20251208T233000 | Bullish | Relevance: 98%
- JPMorgan has identified AstraZeneca (LSE:AZN, NASDAQ:AZN) as its top UK healthcare pick for 2026, emphasizing its catalyst-rich pipeline and high likelihood of clinical success. Conversely, GSK (LSE:GSK, NYSE:GSK) is placed at the bottom due to a "muted" growth outlook and limited trial results expected next year. Other companies like Novartis and Bayer are highlighted for their pipelines and potential for re-rating, respectively, while Novo Nordisk remains a favorite.

**3. 1832 Asset Management L.P. Acquires 18,543 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251207T083206 | Bullish | Relevance: 98%
-  1832 Asset Management L.P. significantly increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 172.9% in Q2, acquiring 18,543 additional shares to bring its total holdings to 29,269 shares valued at $2.045 million. Analysts maintain a "Moderate Buy" consensus rating for AstraZeneca with a target price of $91.67, despite a recent downgrade from Deutsche Bank. The biopharmaceutical company reported strong Q3 earnings, beating EPS and revenue estimates, and its stock is trading near $90 with a market capitalization of approximately $279.7 billion.

**4. Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China**
- Source: Yahoo Finance | 20251208T090000 | Bullish | Relevance: 97%
-  Pillar Biosciences and AstraZeneca have expanded their partnership to China, aiming to provide broader access to NGS-based kitted liquid biopsy tumor profiling. This collaboration seeks to improve diagnostic turnaround times and access to precision oncology solutions in China, a country with a significant cancer burden. The initiative involves working with Shanghai Zhengu Biological Technology to support assay validation and implement Pillar's liquid biopsy panels in local hospital laboratories.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.0B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 17.7 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.3% to -1.1% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.7%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.07% (CS: 45) | Neutral |
| RSI_14 | 61.4 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.28
- **Stop Loss:** $88.18 (3.4% risk)
- **Target:** $94.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 161
- **Position Value:** $14,696.08
- **Portfolio %:** 14.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*